Arcus Biosciences Inc (RCUS) stock saw a decline, ending the day at $15.31 which represents a decrease of $-0.08 or -0.52% from the prior close of $15.39. The stock opened at $15.19 and touched a low ...

Marcus Rashford has made it clear he's disappointed by Manchester United's 3-3 draw with Porto, despite scoring during the ...

On paper, almost everything opposes theMarseille Olympic at SCO Angers, in the opening match of this 7th day of Ligue ...

US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer ...

Hitsuji began serializing the The Magician Who Rose From Failure: Tales of War and Magic story on the "Shōsetsuka ni Narō" ...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform ...

DTCP has invested in Atlantic Hub, a data center developer in Ireland, spotting an opportunity away from more well-trodden ...

"Arcus and AstraZeneca enter trial collaboration for renal cancer treatment" was originally created and published by Clinical ...

Improving oilseed crop yields is critical. India ranks fourth globally in soybean acreage but is only fifth in productivity.

FixMap is an “M&A machine” and the leading player in the Polish fiber-to-the-home (FTTH) market by far, thanks to the ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...